Reuters: Regulatory News: Novartis acute heart failure drug cuts death by 37 pct -study

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Novartis acute heart failure drug cuts death by 37 pct -study Nov 7th 2012, 00:51 LOS ANGELES | Tue Nov 6, 2012 7:51pm EST LOS ANGELES Nov 6 (Reuters) - An experimental Novartis AG drug to treat hospitalized acute heart failure patients reduced deaths by 37 percent compared with a placebo and appeared to be safe, according to data from a pivotal trial presented on Tuesday. The drug, Serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is considered one of the most important medicine's in the Swiss drugmaker's developmental pipeline. "With a meaningful mortality benefit, we believe Serelaxin could represent a $2.5 billion (annual) sales opportunity," Deutsche Bank analysts said in a research note prior to release of the final data at the American Heart Association scientific meeting in Los Angeles. In the study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to marked reduction in worsening of heart failure during hospitalization, researchers said. Patients who received 48 hours of continuously infused serelaxin experienced more than 45 percent fewer episodes of worsening heart failure symptoms than those who got a placebo.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions